Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe - a Hungarian nationwide observational study

BACKGROUND: Infliximab (IFX) has proven to be an effective addition to the therapeutic arsenal for refractory, fistulizing, and steroid dependent Crohn's disease (CD), with efficacy in the induction and maintenance of clinical remission of CD. Our objective in this study is to report the nation...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Miheller, Pál, Lakatos, Péter L, Horváth, Gábor, Molnár, Tamás, Szamosi, Tamás, Czeglédi, Zsófia, Salamon, Ágnes, Czimmer, József, Rumi, György, Palatka, Károly, Papp, Mária, Jakab, Zsolt, Szabó, Andrea, Gelley, András, Lakatos, László, Barta, Zsolt, Balázs, Csaba, Rácz, István, Zeher, Margit, Döbrönte, Zoltán, Altorjay, István, Hunyady, Béla, Simon, László, Papp, János, Banai, János, Nagy, Ferenc, Lonovics, János, Újszászy, László, Műzes, Györgyi, Herszényi, László, Tulassay, Zsolt
التنسيق: Artigo
اللغة:Inglês
منشور في: BioMed Central 2009
الموضوعات:
Research Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC2755473/
https://ncbi.nlm.nih.gov/pubmed/19740450
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-230X-9-66
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة